Close Menu

marketing agreement

The test can detect over 1,000 pathogens — including bacteria, DNA viruses, fungi, mold, and protozoa — from microbial cell-free DNA in a single blood draw.

Regenerative therapeutics company StemCyte will offer Fulgent's Beacon Expanded Carrier Screening and Newborn Genetic Analysis testing services.

The blood-based test, called Melaseq, measures 38 circulating microRNAs that regulate processes that melanoma cells undergo as they become malignant.

Under the terms of the deal, Beijing-based GeneCast has the exclusive right to market Agendia's MammaPrint and BluePrint tests to Chinese customers.

The company has struck a deal to market its tests, including ones based on its Aristotle early cancer detection platform, in collaboration with LifeX.

Dian selected the MassArray system as its platform of choice for molecular genetic testing and will commercialize it and Agena's DNA applications and products.

The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.

The deals cover Plexbio's IntelliPlex 1000 πCode Processor and the PlexBio 100 Fluorescent Analyzer for the IVD and life science research markets.

The five CROs will be able to offer DSP analyses to their customers through a technology access program ahead of NanoString's planned platform launch in 2019.

The companies will comarket Clearbridge's ClearCell CTC system and Leica's Bond Rx staining platform.

Pages

President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.

A study of Great Danes homes in on a genomic region linked to fearfulness.

CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.

In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.